Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
2017 · New England Journal of Medicine · 1,840 citations
https://doi.org/10.1056/nejmoa1612645
S
Shintaro Takao
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
211
Papers
8.4K
Citations
26
h-index
51
i10-index
Shintaro Takao is an academic researcher from National Institute for Environmental Studies. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research. The author has an h-index of 26, co-authored 180 publications.
ORCID: 0000-0002-0118-6447Papers by this author
worksGlobal Carbon Budget 2022
2022 · Earth system science data · 1,712 citations
https://doi.org/10.5194/essd-14-4811-2022
Global Carbon Budget 2023
2023 · Earth system science data · 1,250 citations
https://doi.org/10.5194/essd-15-5301-2023
Global Carbon Budget 2024
2025 · Earth system science data · 382 citations
https://doi.org/10.5194/essd-17-965-2025
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
2012 · Cancer Chemotherapy and Pharmacology · 56 citations
https://doi.org/10.1007/s00280-012-1826-x
Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status
2014 · The Breast · 28 citations
https://doi.org/10.1016/j.breast.2014.03.008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat